"New drugs: Kids come first": Children should be included in trials of new biological treatments

Inflammatory Bowel Diseases

Volumn 13, Issue 9, 2007, Pages 1165-1169

  Cucchiara, Salvatore ^a,b   Morley Fletcher, Alessio ^a   Murphy, M Stephen ^c,d  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b POLICLINICO UMBERTO I   (Italy)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Biological therapy; Crohn's disease; Inflammatory bowel disease; Infliximab; Pediatrics; Ulcerative colitis

Indexed keywords

ADALIMUMAB; AMINOSALICYLIC ACID; ANTIBIOTIC AGENT; AZATHIOPRINE; BASILIXIMAB; C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CORTICOSTEROID RECEPTOR; CYCLOSPORIN; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; MONOCLONAL ANTIBODY CD28; NATALIZUMAB; PLACEBO; TGN 1412; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ACUTE RESPIRATORY FAILURE; APOPTOSIS; BIOLOGICAL THERAPY; CHILD HEALTH; CLINICAL TRIAL; COLON RESECTION; COMBINATION CHEMOTHERAPY; CROHN DISEASE; DISEASE COURSE; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; ENTERITIS; HEPATOSPLENIC T CELL LYMPHOMA; HUMAN; INTESTINE MUCOSA; LYMPHOCYTE DEPLETION HODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REMISSION; REVIEW; RISK ASSESSMENT; SINGLE DRUG DOSE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; T CELL LYMPHOMA; T LYMPHOCYTE; TREATMENT OUTCOME; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

EID: 34548638159     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20045     Document Type: Review

References (0)